{"ticker": {"uuid": "776dfb66-af44-47a1-87c5-67704546cb10", "symbol": "CHRS", "name": "Coherus BioSciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What's Driving Junshi Biosciences' Recent Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxORDJkaDFfajQ1MnJaR2Q5WDBrb25EZW5iOUc1aFV0bEtqUDlxeXNuVWtfcWVRQlBzdFRVTk9vTEVxS000amtBNWdiUW4yVjFHWWhFdnp0QlFCaHVaLUNuN20xSjY3dGVNdGEyNE1HeTN2cFhsN0k3UFMzVlhBZHNLaEh0SDg3R2FWTDZtNA?oc=5", "source_name": "Kavout | AI", "published_at": "2026-07-16T06:21:12+00:00", "published_display": "16 Jul 2026 06:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Coherus BioSciences stock stays supported by oncology focus", "summary": "Coherus BioSciences (CHRS) stock reflects the company's strategic shift towards immuno-oncology while maintaining a biosimilar portfolio. Investors are closely monitoring revenue generation from commercialized biosimilars, the company's cash position, and advancements in its onco", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/coherus-biosciences-stock-stays-supported-by-oncology-focus/69734419", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T20:29:00", "published_display": "09 Jul 2026 20:29", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus BioSciences focuses on biosimilars as investors watch Nasdaq listing", "summary": "Coherus BioSciences is a biopharmaceutical company listed on Nasdaq, specializing in biosimilar and immuno-oncology products. The company aims to provide lower-cost alternatives to established branded therapies and is also developing innovative cancer treatments. Investors are wa", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/coherus-biosciences-focuses-on-biosimilars-as-investors-watch-nasdaq/69713876", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T12:06:48", "published_display": "07 Jul 2026 12:06", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CHRS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Coherus Oncology, Inc. (CHRS) stock, outlining analysts' predictions and historical performance data. It details the company's current stock price, market capitalization, volatility, and future earnings estimates, alongside his", "url": "https://www.tradingview.com/symbols/NASDAQ-CHRS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T11:41:54", "published_display": "26 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI\u00ae (toripalimab-tpzi)", "summary": "Coherus Oncology and Zumutor Biologics have announced a clinical collaboration and supply agreement for a Phase 1 trial evaluating ZM008, an anti-LLT1 monoclonal antibody, in combination with Coherus's PD-1 inhibitor, LOQTORZI. The study will enroll patients with various solid tu", "url": "https://www.globenewswire.com/news-release/2026/06/23/3316369/0/en/coherus-and-zumutor-biologics-announce-clinical-collaboration-to-evaluate-zm008-in-combination-with-loqtorzi-toripalimab-tpzi.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T10:39:54", "published_display": "25 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Coherus Oncology, Inc. \u2013 NASDAQ:CHRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPcE5yTWxSZUZfQUFyWTVXME9Lb0JLb1c5N0VnYTdveGgyNmpRQ2s1RjlRQlYzUV83ZlpGRnRENkRaU3FtRExOY2ktWmNCTVJuQzJVdHBCN0QwNWNLWEtCU3JUcnBtd0hIbHE0Y3hVcHpCMzFodVhaa1RuNkpLcm1Hb1ZFWXd5ZFpsdW9kNFlXRkdadXduSjdmNm04WS0?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T07:18:30+00:00", "published_display": "25 Jun 2026 07:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Enters Trial Collaboration, Supply Agreement With Zumutor Biologics", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/coherus-enters-trial-collaboration-supply-190748394.html", "source_name": "MT Newswires", "published_at": "2026-06-23T19:07:48+00:00", "published_display": "23 Jun 2026 19:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus and Zumutor announce phase 1 cancer trial collaboration", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNSS1OVlhYNkI2MzJOa0FkVVFEaUFmazl1ZTBOckFyWHU2Z2ZNLXNieW1qSXczZllYS1RycDQ3R1NhMV9Zb2dnMzBhejE0SWJuOHJnMjhEZ1JjdzVUZGxRbXdPdDJpdEZMcFlYS0dNVHJSNWw2VkpXczJlOVFiblU5TlU0eEc0UGhqcy1aeV8zcGFtdUdxbC1zc3ZWX3dXSC1UWXdXcUI3R0ZGVTVsWmtwQ1pPdFZzOVg4ZVJESg?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus doses first patient in cancer combo trial with Zumutor", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPOUpYVEFjQTJ1N3JCMEVsWEZKS2xxQXlaV1FBS1JHOERBT2stZFpqcFJUMF9vQXJkNEVhUTBJRDJROUE5ZWo5WWZNU1NBLXdwNG95YS01MXZvcG1fd2lwLWJRZXltQUhoUWNqTVdCdTgzcW96TFdIRHQxbk1yXzlHNmd6b0x5VnBDcTFvbXJaY1ZUT2hrQk9RRkRoQWFzVU9PZXBYcElsN2ZRMUpBQ3JXNV9vQ01ELW5FUFp3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus BioSciences Inc (CHRS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Coherus BioSciences Inc (CHRS), noting its current valuation score of 9.20, which ranks 44th in the Pharmaceuticals industry. It highlights that the company's current P/E ratio is 0.85, significantly lower than its recent high but hig", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-chrs/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:30", "published_display": "18 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus BioSciences Inc (CHRS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Coherus BioSciences Inc (CHRS), identifying major individual and institutional holders, along with their respective proportions. It also presents a breakdown of shareholder types, including investment advisors, corporations, and h", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-chrs/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T00:39:30", "published_display": "18 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus BioSciences Inc (CHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Coherus BioSciences Inc (CHRS), categorizing its revenue by business segment and by region. For the reported period, UDENYCA accounted for the vast majority of revenue at 99.24%, followed by CIMERLI and YUSIMRY. Geographicall", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-chrs/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:30", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus BioSciences Inc (CHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Coherus BioSciences Inc (CHRS) has an earnings forecast score of 8.57, ranking 27th in the Pharmaceuticals industry. Analysts have set an average price target of $5.00 for CHRS, with a \"Buy\" rating based on the consensus of seven analysts. The company's expected revenue for the n", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-chrs/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T13:10:16", "published_display": "17 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young By Investing.com", "summary": "Coherus Oncology has appointed PricewaterhouseCoopers LLP (PwC) as its new independent auditor, replacing Ernst & Young LLP, effective June 12, 2026. The change follows the dismissal of Ernst & Young by the Audit Committee, with Coherus Oncology stating no disagreements on accoun", "url": "https://m.au.investing.com/news/sec-filings/coherus-oncology-appoints-pwc-as-new-auditor-replaces-ernst--young-93CH-4488417?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-16T09:09:28", "published_display": "16 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young", "summary": "Coherus Oncology has announced the dismissal of Ernst & Young LLP as its independent auditor, effective June 12, and the appointment of PricewaterhouseCoopers LLP (PwC) for the fiscal year ending December 31, 2026. The company stated that there were no disagreements on accounting", "url": "https://www.investing.com/news/sec-filings/coherus-oncology-appoints-pwc-as-new-auditor-replaces-ernst--young-93CH-4743297", "source_name": "Investing.com", "published_at": "2026-06-16T03:39:14", "published_display": "16 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Coherus Oncology, Inc. Reports Material Event", "summary": "Coherus Oncology, Inc. filed an 8-K report announcing a change in its independent auditing firm. On June 12, 2026, the company dismissed Ernst & Young LLP and appointed PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026, subject to standard acceptance procedu", "url": "https://www.stocktitan.net/sec-filings/CHRS/8-k-coherus-oncology-inc-reports-material-event-30beab8675a1.html", "source_name": "Stock Titan", "published_at": "2026-06-16T03:02:14", "published_display": "16 Jun 2026 03:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Coherus Oncology, Inc. Reports Material Event | CHRS 8-K Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQbF9tRl9GME9uN2p2aFNXbjg2NkgxZGgzWE5ucEFtbTc2ZjVqSXlNTHZuSTVTaWpzMnl1MUNTZXp5NFFmVHEwSmFjSk9vTFpRbDF3R0wwSnpmWGdLOGtQZ3lBZk1YbE9wRVpEUk9MVlVWV25sMUdKYTloSkNORVhvU0xTMWpBTGlMM053SWoxQkg1OGdsMnZXUXN0M01MLTZMQVBnQmczQzlRd0o5cmc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) director receives 30K RSUs and 60K stock option grant", "summary": "Coherus Oncology director Ali J. Satvat was granted 30,000 restricted stock units (RSUs) and a stock option for 60,000 shares on June 5, 2026. The RSUs vest 100% on June 3, 2027, and the stock option, with an exercise price of $1.45, becomes fully exercisable on June 3, 2027. Bot", "url": "https://www.stocktitan.net/sec-filings/CHRS/form-4-coherus-oncology-inc-insider-trading-activity-0204b15bc129.html", "source_name": "Stock Titan", "published_at": "2026-06-10T19:09:51", "published_display": "10 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Coherus Oncology, Inc. Insider Trading Activity", "summary": "This article reports on insider trading activity at Coherus Oncology, Inc. (CHRS) from a Form 4 filing. It details two transactions by insider Ryan Michael Lee, involving the grant of 30,000 shares of common stock and 60,000 stock options, both vesting over time. The filing impac", "url": "https://www.stocktitan.net/sec-filings/CHRS/form-4-coherus-oncology-inc-insider-trading-activity-ce05320eafe1.html", "source_name": "Stock Titan", "published_at": "2026-06-09T23:09:07", "published_display": "09 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology shareholders approve director elections and equity plan changes", "summary": "Coherus Oncology shareholders held their 2026 Annual Meeting, electing two Class III directors, Dennis M. Lanfear and Mats L. Wahlstr\u00f6m, and ratifying Ernst & Young LLP as their independent public accounting firm. They also approved a non-binding advisory resolution on executive ", "url": "https://www.investing.com/news/sec-filings/coherus-oncology-shareholders-approve-director-elections-and-equity-plan-changes-93CH-4719318", "source_name": "Investing.com", "published_at": "2026-06-05T17:09:12", "published_display": "05 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) shareholders approve equity plan changes and option repricing", "summary": "Coherus Oncology, Inc. shareholders approved all proposals at their 2026 annual meeting, including the election of Class III directors, ratification of Ernst & Young LLP as auditor, and a non-binding Say-on-Pay resolution. Key equity-related approvals included a reduction in the ", "url": "https://www.stocktitan.net/sec-filings/CHRS/8-k-coherus-oncology-inc-reports-material-event-47aca00f33da.html", "source_name": "Stock Titan", "published_at": "2026-06-04T01:10:41", "published_display": "04 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus (NASDAQ: CHRS) reprices 3.2M CEO stock options to $1.59", "summary": "Coherus Oncology, Inc. announced the repricing of 3.2 million stock options for President & CEO Dennis M. Lanfear to an exercise price of $1.59 per share. These new options replace older ones with significantly higher exercise prices, a move approved by stockholders on May 29, 20", "url": "https://www.stocktitan.net/sec-filings/CHRS/form-4-coherus-oncology-inc-insider-trading-activity-fa3cc1e26d40.html", "source_name": "Stock Titan", "published_at": "2026-06-03T11:39:00", "published_display": "03 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Biosciences Announces 2026 Stockholder Meeting Results", "summary": "Coherus Biosciences (CHRS) announced the results of its 2026 Annual Meeting of Stockholders. Key outcomes include the election of Class III directors, ratification of Ernst & Young LLP as auditor, approval of executive compensation, and a reduction in the exercise price of certai", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CHRS-Q/pressreleases/2259548/coherus-biosciences-announces-2026-stockholder-meeting-results/", "source_name": "The Globe and Mail", "published_at": "2026-06-02T22:39:31", "published_display": "02 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CHRS - Coherus Oncology Inc Stock Price and Quote", "summary": "This article provides comprehensive stock information for Coherus Oncology Inc. (CHRS), including its latest stock price, financial overview, analyst ratings, and recent news. Key data points cover market capitalization, P/E ratios, EPS, sales figures, and insider/institutional o", "url": "https://finviz.com/stock?t=CHRS", "source_name": "Finviz", "published_at": "2026-06-01T10:10:51", "published_display": "01 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) CFO receives repriced $1.59 stock options, cancels higher-strike grants", "summary": "Coherus Oncology's CFO, Bryan J. McMichael, received new stock options on May 29, 2026, with an exercise price of $1.59 per share, totaling 220,000 shares. Simultaneously, previously granted options with higher exercise prices, ranging from $5.44 to $14.76 per share, were dispose", "url": "https://www.stocktitan.net/sec-filings/CHRS/form-4-coherus-oncology-inc-insider-trading-activity-3380c1621495.html", "source_name": "Stock Titan", "published_at": "2026-05-31T14:40:33", "published_display": "31 May 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) AGM 2026 Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTFBIcDl4R3RTR2FKSzNjTTM3X0tVeTUwdUNjTDllb3gtMFNCXzR2bW1VSkhxZmotMUhJOFdnQk1BMmN3dmV3eHFzdGxxazJ1T19JMkhyT21RcEtVOGF5di1yanBjdjNpblBxQVlFdmNHZjJSbTg?oc=5", "source_name": "Quartr", "published_at": "2026-05-27T22:35:57+00:00", "published_display": "27 May 2026 22:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus BioSciences stock (US19247A1007): short interest remains elevated as investors watch oncology pipeline", "summary": "Coherus BioSciences (CHRS) continues to experience high short interest and volatile trading as investors assess its oncology and biosimilar portfolios. The company, a US biotechnology firm, is strategically shifting towards high-margin oncology assets while managing its legacy bi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/coherus-biosciences-stock-us19247a1007-short-interest-remains-elevated/69386736", "source_name": "AD HOC NEWS", "published_at": "2026-05-21T02:10:12", "published_display": "21 May 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxQQWZIcXE1bHc0eEkxWk8tUGpZdTJNaGNBUGlXT1J1RWluSlpKblJ6NnZYOFBzQkV0V05pQzZ1TWgzMWw2dHBoVHFDSTJNVTFsZF9JdG5KazRyX1JqVzBTZzZ2RFVxT2t6X2doQ1RlZWstbGJUREp3cV9LUXZfa285RWxlVmdsUEJCMnRjUkF3OFZFLU02RG9FNktFWS1KcU1PVmhrNDNYb0VCcHpFd1U0cTNoSlc1WnlpSnB5MnlZWldFX3F2SEtGNno2UFUxM0FKYVIxbkZad3RITlhMdi04?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "Coherus Oncology reported its first-quarter 2026 financial results, highlighting LOQTORZI\u00ae net revenue of $11.8 million, a 61% increase year-over-year. The company also provided updates on its pipeline, including the completion of patient accrual for the 1L HCC Phase 2 clinical t", "url": "https://www.globenewswire.com/news-release/2026/05/11/3292299/0/en/coherus-oncology-reports-first-quarter-2026-financial-results-and-provides-business-update.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T16:40:08", "published_display": "15 May 2026 16:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What You Need To Know About The Coherus Oncology, Inc. (NASDAQ:CHRS) Analyst Downgrade Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNNm50WHUxc1pxYTNzVmhlNGlQQkh3UHpDTnVpMnZydlI4SDJDWTlyXy1sZ0JRTnBHUVlzVTY0bkZfaVBrNXJuQ3o4cHM4ZkptYXN1ZHUwLWwzZXpQQnZCRTd4WWh0SnlKXzlMNHZqSGVzNmlxTWdQY2p5TDdwMk45VnA1R0RaWEJmYWs0cGluVGJTV1NYZE1vdGtZMFNOZw?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Coherus Oncology: Setting Up For Important Readouts In Mid-2026 (NASDAQ:CHRS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNc3dvVElMUEswTm9nTUtTQ1dGMnR0bVQ2czloUVNsZXVQMVhBQW8ycXNsNTVQWDJWRzhTVElacC1FbUVQa2FTTWRRamhjTktIOC1BcTJkcHNzYmN4c0pmSDhkS3htODNiUEFCMVNEQXVHVzVhcW1nX1JUTmJRZ0FqVUVHWDlCOHhucktvWHVxdG05MEw2RHN2WVQzdVpsRjBEVFdxS1F3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Coherus BioSciences Q1 2026 revenue misses forecast", "summary": "Coherus BioSciences reported Q1 2026 revenue of $12.31 million, falling short of the $14.43 million forecast, but its EPS of -$0.25 met expectations. Despite the revenue miss, the company's shares rose 11.43% in after-hours trading, driven by investor optimism about future growth", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-coherus-biosciences-q1-2026-revenue-misses-forecast-93CH-4678666", "source_name": "Investing.com", "published_at": "2026-05-12T14:08:51", "published_display": "12 May 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/59312a0c-4d32-3d94-8d97-63e1d40e494e/coherus-oncology%2C-inc.-q1.html", "source_name": "Moby", "published_at": "2026-05-12T12:30:00+00:00", "published_display": "12 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology Inc (CHRS) Q1 2026 Earnings Call Highlights: Strong LOQTORZI Sales Growth Amid ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/coherus-oncology-inc-chrs-q1-070753730.html", "source_name": "GuruFocus.com", "published_at": "2026-05-12T07:07:53+00:00", "published_display": "12 May 2026 07:07", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) Reports Q1 Earnings and Updates on LOQTO", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNYVNJZFdjb09pLUNTVlp4aS1KOGZ2cVl4WjZhNmY5eS1hUTRnR3FaM09uelcxQnFCUXV2R0c5b01oMmhsX2dNenFJSkFyR2MwNzRBMGRvWDlUVHJFNmFFeElORDhPeXU1dDhIZExnTGVhdkVJOG1hc0hlY0pjSG8zb3JfdHhLNU51amlZSXY3eERDUC12Rk1KUTl1d3Z4WWdQLXc3eWRmUGRyM3c3dGlreldMdm5uWi16NmJBd1BSN1BMdHNtMUdR?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus BioSciences Inc CHRS", "summary": "This page provides an overview of Coherus BioSciences Inc. (CHRS) stock, including its current price, market cap, and P/E ratio. It shows the stock closed at $1.950 with an 11.43% increase on May 11th. The platform also offers various financial analysis tools and news for investo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-chrs/comments", "source_name": "TradingKey", "published_at": "2026-05-12T02:39:21", "published_display": "12 May 2026 02:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus (CHRS) Reports Q1 Revenue Below Expectations", "summary": "Coherus BioSciences (CHRS) announced Q1 revenue of $12.31 million, falling short of the anticipated $14.34 million. The company, which has a GF Score\u2122 of 51/100, is focusing on its LOQTORZI product for neuroendocrine prostate cancer and other pipeline products, despite facing cha", "url": "https://www.gurufocus.com/news/8849669/coherus-chrs-reports-q1-revenue-below-expectations?mobile=true", "source_name": "GuruFocus", "published_at": "2026-05-12T00:39:21", "published_display": "12 May 2026 00:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/49a4e6c9-51bc-3e04-b798-f4e3e194c03f/coherus-oncology-q1-earnings.html", "source_name": "MarketBeat", "published_at": "2026-05-11T23:05:12+00:00", "published_display": "11 May 2026 23:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/coherus-oncology-q1-earnings-snapshot-202358237.html", "source_name": "Associated Press", "published_at": "2026-05-11T20:23:58+00:00", "published_display": "11 May 2026 20:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) grows Q1 2026 revenue as losses narrow and cash hits $167M", "summary": "Coherus Oncology reported a notable increase in Q1 2026 revenue to $12.3 million from $7.6 million year-over-year, primarily driven by LOQTORZI sales totaling $11.8 million. The company successfully narrowed its GAAP net loss from continuing operations to $36.9 million and mainta", "url": "https://www.stocktitan.net/sec-filings/CHRS/8-k-coherus-oncology-inc-reports-material-event-0c8a0cfea32b.html", "source_name": "Stock Titan", "published_at": "2026-05-11T20:38:51", "published_display": "11 May 2026 20:38", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Biosciences Inc (CHRS) Stock News & Articles", "summary": "This page provides an overview of Coherus BioSciences Inc (CHRS), a biopharmaceutical company specializing in biosimilars and immuno-oncology treatments. It details the company's key products like UDENYCA, CIMERLI, and YUSIMRY, and highlights its strategic partnerships aimed at a", "url": "https://247wallst.com/companies/chrs/", "source_name": "24/7 Wall St.", "published_at": "2026-05-11T11:38:51", "published_display": "11 May 2026 11:38", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOWU5PNlFUNE90V1pMQXhpMEUxRHJjb2s4WmtPX0ExTEtTdFNSbXk0czN2T2dVYzBPNmJseEg0MFhNRjk3cXlyQUc3dkQ3WDRmdE5HTklHcnZDWmF3LUgxRnY0MVdJMnBrY085T3ZiTGstTFI2OUZiTlc2Y0hJUzhMeDRFSjNaZENsUWVpa0s4U000Q2p2ZWNnM2JqbnBldw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026", "summary": "Coherus Oncology, Inc. announced it will release its first quarter 2026 financial results after market close on Monday, May 11, 2026. The company's management will host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a business update. A", "url": "https://www.globenewswire.com/news-release/2026/05/04/3286820/33333/en/Coherus-Oncology-to-Report-First-Quarter-2026-Financial-R", "source_name": "GlobeNewswire", "published_at": "2026-05-05T11:09:00", "published_display": "05 May 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus sets May 11 after-close call for Q1 results, business update", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPMkYxMW1HV3VDSS0zSVBubEJaMmNxZ2EtTDJpOEwwV003aXVZTzJUekVoMmg2M2hFWThlTUJNWHUySDJfZ28xbUFIN2FGYWkxU09UZjFfLV9aREctdUYzem5qQVp6eElmc1d0d2ZEMTB2cktvRmNfQnhmWXpwSFdRVktIbkEzbFdnQ25OT1Vfd0NNUGtDSHhaT0lua0ZDX1NlZ2VZUkFaZEg4RWVqWTdMN295SlQwM2tHT1NrSWx3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satterfield reports 6.93M shares in Coherus Oncology (NASDAQ: CHRS) ownership filing", "summary": "Thomas A. Satterfield, Jr. has filed a Schedule 13G/A, reporting beneficial ownership of 6.93 million shares, or 4.6%, of Coherus Oncology (NASDAQ: CHRS) common stock. This includes shares held jointly, through various entities he controls, and via limited powers of attorney for ", "url": "https://www.stocktitan.net/sec-filings/CHRS/schedule-13g-a-coherus-oncology-inc-amended-passive-investment-disclo-3701c48e652e.html", "source_name": "Stock Titan", "published_at": "2026-04-30T08:09:46", "published_display": "30 Apr 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Coherus Oncology (CHRS) Is One of the Best Penny Stocks, Here is Why \u2013 Corrected", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPRUZhTW91RG93NWYxajBxeGZxRk5HTFpmUnhXMFFTWUs2bXpsbUdHZFBoVXBrb0t4RDFXdklhLVdEcmJFSi13aEZKVy1KNXFDOHkyYy1OOTQ3Y2RRTnJZZVRHTk1FYThjUUdWb2RveTBkaldKbENfOXVIc3h5aGF1UWNkckh0RkJBd0ZWOVhKWmpLNEhySHRialp6THI5X2c?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why The Coherus Oncology (CHRS) Story Is Shifting Around Growth Assumptions And Execution Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQR2YwTE1iS184MnR1TllVNHB6ckUyUXNleWVIME5TV3NETVpNVmI5eVVXVjZzQTZZVGU5N3hlMzdOclFTNjkzNDF3X0VGYnp3LThCc0o4RUduT0tJcnc4VzhsSXZTMk1TeVZvclpRdUpCNlp4YWM0SHpUY05UOUxYVnVTRlBkZzZSZVAwRWttVXdjd2FMQVBucS1WWkZhWWJVY1E?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQWmNqN1dzcXNWNS13V1hVc0lSOHYyNVpoN3lkUlA1V2pJMThPMVRtdmZMQi1ZVHJEWmExTVF6MGgzOTJCVUpSRUVWbmk2QnJxMTJfVlRrQS1BQ3k4YXdWTzNiN3RaQUJqOTJ1MXRjYlpBV0s3Y2loOTI3Wm9OVVRwbkxJRnE?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPZDkyWTliV3FiUTRZT0k3ektIeGo0WVlSbFI3Z195aTNiNjQ4RVdSeEhrYTF2VXF0dDY2UGtVekJ6U0FCTXViNk1KRHNCclhwRHV1cjBDZE44Q3RCSll1aVVvOTVTbFY5aXA1VExSc0dnVnpCZGlwdldWLWJsY0YxczN1VF9SN2UxZDNvZkpR?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Biosciences stock gains on JNJ clinical supply agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPMC1iVGFVWWh6bnhYMks0Mkt2Q2lwUnNEdG13RG5xSkhlNFFVZEt0WTl6d3JmYVF6eWppZE5XTjdZVk1xQ19DOFNYR1J5MllNal8zOVNJTVVVYkNhVk1mOTFfQ1NFTjNCTmRXV0R3YnJRaWMzbjF3SG1FNHBTOEIwMnFFa1RyZ0p6R0xtZDlmeW82RURoS3V0Snl1WkhYM1NFUHJETWo4YWstcHI2X195Ti1udHNkY2Z4b0x1cHJwRTc1Zw?oc=5", "source_name": "Investing.com", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) Taps ATM Facility: Strategic Lifeline or Dilution Trade-Off for Its Pipeline?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "What's Driving Junshi Biosciences' Recent Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxORDJkaDFfajQ1MnJaR2Q5WDBrb25EZW5iOUc1aFV0bEtqUDlxeXNuVWtfcWVRQlBzdFRVTk9vTEVxS000amtBNWdiUW4yVjFHWWhFdnp0QlFCaHVaLUNuN20xSjY3dGVNdGEyNE1HeTN2cFhsN0k3UFMzVlhBZHNLaEh0SDg3R2FWTDZtNA?oc=5", "source_name": "Kavout | AI", "published_at": "2026-07-16T06:21:12+00:00", "published_display": "16 Jul 2026 06:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus BioSciences stock stays supported by oncology focus", "summary": "Coherus BioSciences (CHRS) stock reflects the company's strategic shift towards immuno-oncology while maintaining a biosimilar portfolio. Investors are closely monitoring revenue generation from commercialized biosimilars, the company's cash position, and advancements in its onco", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/coherus-biosciences-stock-stays-supported-by-oncology-focus/69734419", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T20:29:00", "published_display": "09 Jul 2026 20:29", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus BioSciences focuses on biosimilars as investors watch Nasdaq listing", "summary": "Coherus BioSciences is a biopharmaceutical company listed on Nasdaq, specializing in biosimilar and immuno-oncology products. The company aims to provide lower-cost alternatives to established branded therapies and is also developing innovative cancer treatments. Investors are wa", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/coherus-biosciences-focuses-on-biosimilars-as-investors-watch-nasdaq/69713876", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T12:06:48", "published_display": "07 Jul 2026 12:06", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CHRS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Coherus Oncology, Inc. (CHRS) stock, outlining analysts' predictions and historical performance data. It details the company's current stock price, market capitalization, volatility, and future earnings estimates, alongside his", "url": "https://www.tradingview.com/symbols/NASDAQ-CHRS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T11:41:54", "published_display": "26 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI\u00ae (toripalimab-tpzi)", "summary": "Coherus Oncology and Zumutor Biologics have announced a clinical collaboration and supply agreement for a Phase 1 trial evaluating ZM008, an anti-LLT1 monoclonal antibody, in combination with Coherus's PD-1 inhibitor, LOQTORZI. The study will enroll patients with various solid tu", "url": "https://www.globenewswire.com/news-release/2026/06/23/3316369/0/en/coherus-and-zumutor-biologics-announce-clinical-collaboration-to-evaluate-zm008-in-combination-with-loqtorzi-toripalimab-tpzi.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T10:39:54", "published_display": "25 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Coherus Oncology, Inc. \u2013 NASDAQ:CHRS", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPcE5yTWxSZUZfQUFyWTVXME9Lb0JLb1c5N0VnYTdveGgyNmpRQ2s1RjlRQlYzUV83ZlpGRnRENkRaU3FtRExOY2ktWmNCTVJuQzJVdHBCN0QwNWNLWEtCU3JUcnBtd0hIbHE0Y3hVcHpCMzFodVhaa1RuNkpLcm1Hb1ZFWXd5ZFpsdW9kNFlXRkdadXduSjdmNm04WS0?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T07:18:30+00:00", "published_display": "25 Jun 2026 07:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Enters Trial Collaboration, Supply Agreement With Zumutor Biologics", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/coherus-enters-trial-collaboration-supply-190748394.html", "source_name": "MT Newswires", "published_at": "2026-06-23T19:07:48+00:00", "published_display": "23 Jun 2026 19:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus and Zumutor announce phase 1 cancer trial collaboration", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNSS1OVlhYNkI2MzJOa0FkVVFEaUFmazl1ZTBOckFyWHU2Z2ZNLXNieW1qSXczZllYS1RycDQ3R1NhMV9Zb2dnMzBhejE0SWJuOHJnMjhEZ1JjdzVUZGxRbXdPdDJpdEZMcFlYS0dNVHJSNWw2VkpXczJlOVFiblU5TlU0eEc0UGhqcy1aeV8zcGFtdUdxbC1zc3ZWX3dXSC1UWXdXcUI3R0ZGVTVsWmtwQ1pPdFZzOVg4ZVJESg?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus doses first patient in cancer combo trial with Zumutor", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPOUpYVEFjQTJ1N3JCMEVsWEZKS2xxQXlaV1FBS1JHOERBT2stZFpqcFJUMF9vQXJkNEVhUTBJRDJROUE5ZWo5WWZNU1NBLXdwNG95YS01MXZvcG1fd2lwLWJRZXltQUhoUWNqTVdCdTgzcW96TFdIRHQxbk1yXzlHNmd6b0x5VnBDcTFvbXJaY1ZUT2hrQk9RRkRoQWFzVU9PZXBYcElsN2ZRMUpBQ3JXNV9vQ01ELW5FUFp3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus BioSciences Inc (CHRS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Coherus BioSciences Inc (CHRS), noting its current valuation score of 9.20, which ranks 44th in the Pharmaceuticals industry. It highlights that the company's current P/E ratio is 0.85, significantly lower than its recent high but hig", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-chrs/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:30", "published_display": "18 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus BioSciences Inc (CHRS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Coherus BioSciences Inc (CHRS), identifying major individual and institutional holders, along with their respective proportions. It also presents a breakdown of shareholder types, including investment advisors, corporations, and h", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-chrs/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T00:39:30", "published_display": "18 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus BioSciences Inc (CHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Coherus BioSciences Inc (CHRS), categorizing its revenue by business segment and by region. For the reported period, UDENYCA accounted for the vast majority of revenue at 99.24%, followed by CIMERLI and YUSIMRY. Geographicall", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-chrs/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:30", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus BioSciences Inc (CHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Coherus BioSciences Inc (CHRS) has an earnings forecast score of 8.57, ranking 27th in the Pharmaceuticals industry. Analysts have set an average price target of $5.00 for CHRS, with a \"Buy\" rating based on the consensus of seven analysts. The company's expected revenue for the n", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-chrs/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T13:10:16", "published_display": "17 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young By Investing.com", "summary": "Coherus Oncology has appointed PricewaterhouseCoopers LLP (PwC) as its new independent auditor, replacing Ernst & Young LLP, effective June 12, 2026. The change follows the dismissal of Ernst & Young by the Audit Committee, with Coherus Oncology stating no disagreements on accoun", "url": "https://m.au.investing.com/news/sec-filings/coherus-oncology-appoints-pwc-as-new-auditor-replaces-ernst--young-93CH-4488417?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-16T09:09:28", "published_display": "16 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young", "summary": "Coherus Oncology has announced the dismissal of Ernst & Young LLP as its independent auditor, effective June 12, and the appointment of PricewaterhouseCoopers LLP (PwC) for the fiscal year ending December 31, 2026. The company stated that there were no disagreements on accounting", "url": "https://www.investing.com/news/sec-filings/coherus-oncology-appoints-pwc-as-new-auditor-replaces-ernst--young-93CH-4743297", "source_name": "Investing.com", "published_at": "2026-06-16T03:39:14", "published_display": "16 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Coherus Oncology, Inc. Reports Material Event", "summary": "Coherus Oncology, Inc. filed an 8-K report announcing a change in its independent auditing firm. On June 12, 2026, the company dismissed Ernst & Young LLP and appointed PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026, subject to standard acceptance procedu", "url": "https://www.stocktitan.net/sec-filings/CHRS/8-k-coherus-oncology-inc-reports-material-event-30beab8675a1.html", "source_name": "Stock Titan", "published_at": "2026-06-16T03:02:14", "published_display": "16 Jun 2026 03:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Coherus Oncology, Inc. Reports Material Event | CHRS 8-K Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQbF9tRl9GME9uN2p2aFNXbjg2NkgxZGgzWE5ucEFtbTc2ZjVqSXlNTHZuSTVTaWpzMnl1MUNTZXp5NFFmVHEwSmFjSk9vTFpRbDF3R0wwSnpmWGdLOGtQZ3lBZk1YbE9wRVpEUk9MVlVWV25sMUdKYTloSkNORVhvU0xTMWpBTGlMM053SWoxQkg1OGdsMnZXUXN0M01MLTZMQVBnQmczQzlRd0o5cmc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) director receives 30K RSUs and 60K stock option grant", "summary": "Coherus Oncology director Ali J. Satvat was granted 30,000 restricted stock units (RSUs) and a stock option for 60,000 shares on June 5, 2026. The RSUs vest 100% on June 3, 2027, and the stock option, with an exercise price of $1.45, becomes fully exercisable on June 3, 2027. Bot", "url": "https://www.stocktitan.net/sec-filings/CHRS/form-4-coherus-oncology-inc-insider-trading-activity-0204b15bc129.html", "source_name": "Stock Titan", "published_at": "2026-06-10T19:09:51", "published_display": "10 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Coherus Oncology, Inc. Insider Trading Activity", "summary": "This article reports on insider trading activity at Coherus Oncology, Inc. (CHRS) from a Form 4 filing. It details two transactions by insider Ryan Michael Lee, involving the grant of 30,000 shares of common stock and 60,000 stock options, both vesting over time. The filing impac", "url": "https://www.stocktitan.net/sec-filings/CHRS/form-4-coherus-oncology-inc-insider-trading-activity-ce05320eafe1.html", "source_name": "Stock Titan", "published_at": "2026-06-09T23:09:07", "published_display": "09 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology shareholders approve director elections and equity plan changes", "summary": "Coherus Oncology shareholders held their 2026 Annual Meeting, electing two Class III directors, Dennis M. Lanfear and Mats L. Wahlstr\u00f6m, and ratifying Ernst & Young LLP as their independent public accounting firm. They also approved a non-binding advisory resolution on executive ", "url": "https://www.investing.com/news/sec-filings/coherus-oncology-shareholders-approve-director-elections-and-equity-plan-changes-93CH-4719318", "source_name": "Investing.com", "published_at": "2026-06-05T17:09:12", "published_display": "05 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) shareholders approve equity plan changes and option repricing", "summary": "Coherus Oncology, Inc. shareholders approved all proposals at their 2026 annual meeting, including the election of Class III directors, ratification of Ernst & Young LLP as auditor, and a non-binding Say-on-Pay resolution. Key equity-related approvals included a reduction in the ", "url": "https://www.stocktitan.net/sec-filings/CHRS/8-k-coherus-oncology-inc-reports-material-event-47aca00f33da.html", "source_name": "Stock Titan", "published_at": "2026-06-04T01:10:41", "published_display": "04 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus (NASDAQ: CHRS) reprices 3.2M CEO stock options to $1.59", "summary": "Coherus Oncology, Inc. announced the repricing of 3.2 million stock options for President & CEO Dennis M. Lanfear to an exercise price of $1.59 per share. These new options replace older ones with significantly higher exercise prices, a move approved by stockholders on May 29, 20", "url": "https://www.stocktitan.net/sec-filings/CHRS/form-4-coherus-oncology-inc-insider-trading-activity-fa3cc1e26d40.html", "source_name": "Stock Titan", "published_at": "2026-06-03T11:39:00", "published_display": "03 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Biosciences Announces 2026 Stockholder Meeting Results", "summary": "Coherus Biosciences (CHRS) announced the results of its 2026 Annual Meeting of Stockholders. Key outcomes include the election of Class III directors, ratification of Ernst & Young LLP as auditor, approval of executive compensation, and a reduction in the exercise price of certai", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CHRS-Q/pressreleases/2259548/coherus-biosciences-announces-2026-stockholder-meeting-results/", "source_name": "The Globe and Mail", "published_at": "2026-06-02T22:39:31", "published_display": "02 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CHRS - Coherus Oncology Inc Stock Price and Quote", "summary": "This article provides comprehensive stock information for Coherus Oncology Inc. (CHRS), including its latest stock price, financial overview, analyst ratings, and recent news. Key data points cover market capitalization, P/E ratios, EPS, sales figures, and insider/institutional o", "url": "https://finviz.com/stock?t=CHRS", "source_name": "Finviz", "published_at": "2026-06-01T10:10:51", "published_display": "01 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) CFO receives repriced $1.59 stock options, cancels higher-strike grants", "summary": "Coherus Oncology's CFO, Bryan J. McMichael, received new stock options on May 29, 2026, with an exercise price of $1.59 per share, totaling 220,000 shares. Simultaneously, previously granted options with higher exercise prices, ranging from $5.44 to $14.76 per share, were dispose", "url": "https://www.stocktitan.net/sec-filings/CHRS/form-4-coherus-oncology-inc-insider-trading-activity-3380c1621495.html", "source_name": "Stock Titan", "published_at": "2026-05-31T14:40:33", "published_display": "31 May 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) AGM 2026 Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTFBIcDl4R3RTR2FKSzNjTTM3X0tVeTUwdUNjTDllb3gtMFNCXzR2bW1VSkhxZmotMUhJOFdnQk1BMmN3dmV3eHFzdGxxazJ1T19JMkhyT21RcEtVOGF5di1yanBjdjNpblBxQVlFdmNHZjJSbTg?oc=5", "source_name": "Quartr", "published_at": "2026-05-27T22:35:57+00:00", "published_display": "27 May 2026 22:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus BioSciences stock (US19247A1007): short interest remains elevated as investors watch oncology pipeline", "summary": "Coherus BioSciences (CHRS) continues to experience high short interest and volatile trading as investors assess its oncology and biosimilar portfolios. The company, a US biotechnology firm, is strategically shifting towards high-margin oncology assets while managing its legacy bi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/coherus-biosciences-stock-us19247a1007-short-interest-remains-elevated/69386736", "source_name": "AD HOC NEWS", "published_at": "2026-05-21T02:10:12", "published_display": "21 May 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxQQWZIcXE1bHc0eEkxWk8tUGpZdTJNaGNBUGlXT1J1RWluSlpKblJ6NnZYOFBzQkV0V05pQzZ1TWgzMWw2dHBoVHFDSTJNVTFsZF9JdG5KazRyX1JqVzBTZzZ2RFVxT2t6X2doQ1RlZWstbGJUREp3cV9LUXZfa285RWxlVmdsUEJCMnRjUkF3OFZFLU02RG9FNktFWS1KcU1PVmhrNDNYb0VCcHpFd1U0cTNoSlc1WnlpSnB5MnlZWldFX3F2SEtGNno2UFUxM0FKYVIxbkZad3RITlhMdi04?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "Coherus Oncology reported its first-quarter 2026 financial results, highlighting LOQTORZI\u00ae net revenue of $11.8 million, a 61% increase year-over-year. The company also provided updates on its pipeline, including the completion of patient accrual for the 1L HCC Phase 2 clinical t", "url": "https://www.globenewswire.com/news-release/2026/05/11/3292299/0/en/coherus-oncology-reports-first-quarter-2026-financial-results-and-provides-business-update.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T16:40:08", "published_display": "15 May 2026 16:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What You Need To Know About The Coherus Oncology, Inc. (NASDAQ:CHRS) Analyst Downgrade Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNNm50WHUxc1pxYTNzVmhlNGlQQkh3UHpDTnVpMnZydlI4SDJDWTlyXy1sZ0JRTnBHUVlzVTY0bkZfaVBrNXJuQ3o4cHM4ZkptYXN1ZHUwLWwzZXpQQnZCRTd4WWh0SnlKXzlMNHZqSGVzNmlxTWdQY2p5TDdwMk45VnA1R0RaWEJmYWs0cGluVGJTV1NYZE1vdGtZMFNOZw?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology: Setting Up For Important Readouts In Mid-2026 (NASDAQ:CHRS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNc3dvVElMUEswTm9nTUtTQ1dGMnR0bVQ2czloUVNsZXVQMVhBQW8ycXNsNTVQWDJWRzhTVElacC1FbUVQa2FTTWRRamhjTktIOC1BcTJkcHNzYmN4c0pmSDhkS3htODNiUEFCMVNEQXVHVzVhcW1nX1JUTmJRZ0FqVUVHWDlCOHhucktvWHVxdG05MEw2RHN2WVQzdVpsRjBEVFdxS1F3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Coherus BioSciences Q1 2026 revenue misses forecast", "summary": "Coherus BioSciences reported Q1 2026 revenue of $12.31 million, falling short of the $14.43 million forecast, but its EPS of -$0.25 met expectations. Despite the revenue miss, the company's shares rose 11.43% in after-hours trading, driven by investor optimism about future growth", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-coherus-biosciences-q1-2026-revenue-misses-forecast-93CH-4678666", "source_name": "Investing.com", "published_at": "2026-05-12T14:08:51", "published_display": "12 May 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/59312a0c-4d32-3d94-8d97-63e1d40e494e/coherus-oncology%2C-inc.-q1.html", "source_name": "Moby", "published_at": "2026-05-12T12:30:00+00:00", "published_display": "12 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology Inc (CHRS) Q1 2026 Earnings Call Highlights: Strong LOQTORZI Sales Growth Amid ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/coherus-oncology-inc-chrs-q1-070753730.html", "source_name": "GuruFocus.com", "published_at": "2026-05-12T07:07:53+00:00", "published_display": "12 May 2026 07:07", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) Reports Q1 Earnings and Updates on LOQTO", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNYVNJZFdjb09pLUNTVlp4aS1KOGZ2cVl4WjZhNmY5eS1hUTRnR3FaM09uelcxQnFCUXV2R0c5b01oMmhsX2dNenFJSkFyR2MwNzRBMGRvWDlUVHJFNmFFeElORDhPeXU1dDhIZExnTGVhdkVJOG1hc0hlY0pjSG8zb3JfdHhLNU51amlZSXY3eERDUC12Rk1KUTl1d3Z4WWdQLXc3eWRmUGRyM3c3dGlreldMdm5uWi16NmJBd1BSN1BMdHNtMUdR?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus BioSciences Inc CHRS", "summary": "This page provides an overview of Coherus BioSciences Inc. (CHRS) stock, including its current price, market cap, and P/E ratio. It shows the stock closed at $1.950 with an 11.43% increase on May 11th. The platform also offers various financial analysis tools and news for investo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-chrs/comments", "source_name": "TradingKey", "published_at": "2026-05-12T02:39:21", "published_display": "12 May 2026 02:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus (CHRS) Reports Q1 Revenue Below Expectations", "summary": "Coherus BioSciences (CHRS) announced Q1 revenue of $12.31 million, falling short of the anticipated $14.34 million. The company, which has a GF Score\u2122 of 51/100, is focusing on its LOQTORZI product for neuroendocrine prostate cancer and other pipeline products, despite facing cha", "url": "https://www.gurufocus.com/news/8849669/coherus-chrs-reports-q1-revenue-below-expectations?mobile=true", "source_name": "GuruFocus", "published_at": "2026-05-12T00:39:21", "published_display": "12 May 2026 00:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/49a4e6c9-51bc-3e04-b798-f4e3e194c03f/coherus-oncology-q1-earnings.html", "source_name": "MarketBeat", "published_at": "2026-05-11T23:05:12+00:00", "published_display": "11 May 2026 23:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/coherus-oncology-q1-earnings-snapshot-202358237.html", "source_name": "Associated Press", "published_at": "2026-05-11T20:23:58+00:00", "published_display": "11 May 2026 20:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) grows Q1 2026 revenue as losses narrow and cash hits $167M", "summary": "Coherus Oncology reported a notable increase in Q1 2026 revenue to $12.3 million from $7.6 million year-over-year, primarily driven by LOQTORZI sales totaling $11.8 million. The company successfully narrowed its GAAP net loss from continuing operations to $36.9 million and mainta", "url": "https://www.stocktitan.net/sec-filings/CHRS/8-k-coherus-oncology-inc-reports-material-event-0c8a0cfea32b.html", "source_name": "Stock Titan", "published_at": "2026-05-11T20:38:51", "published_display": "11 May 2026 20:38", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Biosciences Inc (CHRS) Stock News & Articles", "summary": "This page provides an overview of Coherus BioSciences Inc (CHRS), a biopharmaceutical company specializing in biosimilars and immuno-oncology treatments. It details the company's key products like UDENYCA, CIMERLI, and YUSIMRY, and highlights its strategic partnerships aimed at a", "url": "https://247wallst.com/companies/chrs/", "source_name": "24/7 Wall St.", "published_at": "2026-05-11T11:38:51", "published_display": "11 May 2026 11:38", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOWU5PNlFUNE90V1pMQXhpMEUxRHJjb2s4WmtPX0ExTEtTdFNSbXk0czN2T2dVYzBPNmJseEg0MFhNRjk3cXlyQUc3dkQ3WDRmdE5HTklHcnZDWmF3LUgxRnY0MVdJMnBrY085T3ZiTGstTFI2OUZiTlc2Y0hJUzhMeDRFSjNaZENsUWVpa0s4U000Q2p2ZWNnM2JqbnBldw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026", "summary": "Coherus Oncology, Inc. announced it will release its first quarter 2026 financial results after market close on Monday, May 11, 2026. The company's management will host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a business update. A", "url": "https://www.globenewswire.com/news-release/2026/05/04/3286820/33333/en/Coherus-Oncology-to-Report-First-Quarter-2026-Financial-R", "source_name": "GlobeNewswire", "published_at": "2026-05-05T11:09:00", "published_display": "05 May 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus sets May 11 after-close call for Q1 results, business update", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPMkYxMW1HV3VDSS0zSVBubEJaMmNxZ2EtTDJpOEwwV003aXVZTzJUekVoMmg2M2hFWThlTUJNWHUySDJfZ28xbUFIN2FGYWkxU09UZjFfLV9aREctdUYzem5qQVp6eElmc1d0d2ZEMTB2cktvRmNfQnhmWXpwSFdRVktIbkEzbFdnQ25OT1Vfd0NNUGtDSHhaT0lua0ZDX1NlZ2VZUkFaZEg4RWVqWTdMN295SlQwM2tHT1NrSWx3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satterfield reports 6.93M shares in Coherus Oncology (NASDAQ: CHRS) ownership filing", "summary": "Thomas A. Satterfield, Jr. has filed a Schedule 13G/A, reporting beneficial ownership of 6.93 million shares, or 4.6%, of Coherus Oncology (NASDAQ: CHRS) common stock. This includes shares held jointly, through various entities he controls, and via limited powers of attorney for ", "url": "https://www.stocktitan.net/sec-filings/CHRS/schedule-13g-a-coherus-oncology-inc-amended-passive-investment-disclo-3701c48e652e.html", "source_name": "Stock Titan", "published_at": "2026-04-30T08:09:46", "published_display": "30 Apr 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) Is One of the Best Penny Stocks, Here is Why \u2013 Corrected", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPRUZhTW91RG93NWYxajBxeGZxRk5HTFpmUnhXMFFTWUs2bXpsbUdHZFBoVXBrb0t4RDFXdklhLVdEcmJFSi13aEZKVy1KNXFDOHkyYy1OOTQ3Y2RRTnJZZVRHTk1FYThjUUdWb2RveTBkaldKbENfOXVIc3h5aGF1UWNkckh0RkJBd0ZWOVhKWmpLNEhySHRialp6THI5X2c?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why The Coherus Oncology (CHRS) Story Is Shifting Around Growth Assumptions And Execution Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQR2YwTE1iS184MnR1TllVNHB6ckUyUXNleWVIME5TV3NETVpNVmI5eVVXVjZzQTZZVGU5N3hlMzdOclFTNjkzNDF3X0VGYnp3LThCc0o4RUduT0tJcnc4VzhsSXZTMk1TeVZvclpRdUpCNlp4YWM0SHpUY05UOUxYVnVTRlBkZzZSZVAwRWttVXdjd2FMQVBucS1WWkZhWWJVY1E?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQWmNqN1dzcXNWNS13V1hVc0lSOHYyNVpoN3lkUlA1V2pJMThPMVRtdmZMQi1ZVHJEWmExTVF6MGgzOTJCVUpSRUVWbmk2QnJxMTJfVlRrQS1BQ3k4YXdWTzNiN3RaQUJqOTJ1MXRjYlpBV0s3Y2loOTI3Wm9OVVRwbkxJRnE?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPZDkyWTliV3FiUTRZT0k3ektIeGo0WVlSbFI3Z195aTNiNjQ4RVdSeEhrYTF2VXF0dDY2UGtVekJ6U0FCTXViNk1KRHNCclhwRHV1cjBDZE44Q3RCSll1aVVvOTVTbFY5aXA1VExSc0dnVnpCZGlwdldWLWJsY0YxczN1VF9SN2UxZDNvZkpR?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Biosciences stock gains on JNJ clinical supply agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPMC1iVGFVWWh6bnhYMks0Mkt2Q2lwUnNEdG13RG5xSkhlNFFVZEt0WTl6d3JmYVF6eWppZE5XTjdZVk1xQ19DOFNYR1J5MllNal8zOVNJTVVVYkNhVk1mOTFfQ1NFTjNCTmRXV0R3YnJRaWMzbjF3SG1FNHBTOEIwMnFFa1RyZ0p6R0xtZDlmeW82RURoS3V0Snl1WkhYM1NFUHJETWo4YWstcHI2X195Ti1udHNkY2Z4b0x1cHJwRTc1Zw?oc=5", "source_name": "Investing.com", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coherus Oncology (CHRS) Taps ATM Facility: Strategic Lifeline or Dilution Trade-Off for Its Pipeline?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 111, "total_relevant": 73, "sentiment_summary": {"positive": 15, "negative": 6, "neutral": 52, "score": 52, "total": 73, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 19.95, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 15.06, "count": 29}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "macro", "label": "Macro sensitivity", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 1.54, "latest_week": "2026-07-10", "one_week_move": 6.2, "four_week_move": 10.0, "twelve_week_move": -22.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.894706, "market_dynamics_buy_signal": false, "relative_strength": -11.89557, "fair_value_gap": -15.1, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 40.9479, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.2% over one week, +10.0% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 59, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 11}, {"label": "Investing.com", "count": 6}, {"label": "TradingKey", "count": 5}, {"label": "TradingView", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "The Globe and Mail", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 64}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 29}, {"label": "Deals and strategy", "count": 4}, {"label": "Macro sensitivity", "count": 3}, {"label": "Analyst action", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "64", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+6.2% over one week, +10.0% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "What's Driving Junshi Biosciences' Recent Momentum"}], "updated_at": "2026-07-17T04:24:51.006800+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}